Imidazotriazine derivatives acting as interleukin-17 (IL-17) modulators have been described in a UCB SA patent and are reported to be potentially useful for the treatment of inflammatory disorders and autoimmune diseases.
A Sanofi SA patent describes imidazopyridine compounds acting as mitogen-activated protein kinase 7 (MAPK7; ERK5) inhibitors and reported to be useful for the treatment of cancer.
Pompe disease is a disorder caused by deficiency of the lysosomal acid α-glucosidase (GAA) enzyme, which leads to the accumulation of glycogen within the lysosomes, overall in skeletal and cardiac muscle.
Because selective BET inhibitors present better efficacy and safety than pan-BET inhibitors, current research is focused on the development of BD1- or BD2-selective inhibitors.
Almirall S.A. has entered into an exclusive license agreement with Novo Nordisk A/S for global rights to develop and commercialize the IL-21-blocking monoclonal antibody NN-8828 in certain fields, including immune inflammatory dermatological diseases.
The company has developed a method of transplantation of human hematopoietic stem cells that allows their engraftment and differentiation into microglial cells.
Researchers at the University of Ottawa have reported on the use of vanoxerine as a suppressor of CSC tumorigenic activity in preclinical models of colorectal cancer.
RSS
